Southern Shuanglin shareholders approve capital management proposals

Southern Shuanglin Bio-Pharmacy held its third extraordinary general meeting of shareholders on November 13, 2025. All proposed resolutions were approved, confirming shareholder support for the company's strategic decisions. The meeting utilized a combination of on-site and online voting, with 347 shareholders representing 346,536,800 shares, or 36.4623% of the total voting rights, participating.

The primary resolutions included a proposal to change the use of raised funds and a proposal to permanently replenish working capital with surplus raised funds from certain investment projects. The proposal to change the use of raised funds received overwhelming approval with 342,973,716 votes (98.9718%) in favor. The resolution to use surplus funds for working capital also passed with strong support, garnering 343,107,876 votes (99.0105%) in favor.

The meeting procedures, conveners, attendees' qualifications, and the voting process were deemed compliant with relevant laws and regulations by Beijing Jiayuan Law Firm, ensuring the validity of the resolutions.